SOURCE: Arch Therapeutics, Inc.

Arch Therapeutics, Inc.

February 08, 2017 07:57 ET

Arch Therapeutics to Provide Corporate Updates at Two Conferences in New York, February 2017

Dr. Norchi to Present at the 19th Annual BIO CEO & Investor Conference and 2nd Annual Source Capital Disruptive Growth & Healthcare Conference

FRAMINGHAM, MA--(Marketwired - Feb 8, 2017) - Terrence Norchi, MD, CEO of Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and wound care devices, will present at the BIO CEO & Investor Conference and the Source Capital Disruptive Growth & Healthcare Conference, both held in New York City.

Dr. Norchi is scheduled to present at the 19th Annual BIO CEO & Investor Conference on Tuesday, February 14 at 2:30 PM ET at the Waldorf Astoria in New York City. He will be available to participate in meetings with investors who are registered to attend the conference. If you are an investor and wish to attend the Company's presentation or schedule a meeting, please click the following link: https://www.bio.org/events/bio-ceo-investor-conference.

Dr. Norchi is also scheduled to provide a company update during a live webcast at the Source Capital Disruptive Growth & Healthcare Conference on Thursday, February 16 at 10:45 AM ET at the Convene Conference Center located at 730 Third Avenue, New York City. If you wish to attend the presentation or schedule a meeting, please click the following link: http://disruptnyc.com. You may access the live webcast by visiting: http://www.investorcalendar.com/event/11170. The presentation will be available for download at: http://ir.archtherapeutics.com.

About Arch Therapeutics, Inc.

Arch Therapeutics, Inc. is a medical device company developing a novel approach to stop bleeding (hemostasis) and control leaking (sealant) during surgery and trauma care. Arch is developing products based on an innovative self-assembling materials technology platform with the goal of making surgery and interventional care faster and safer for patients. Arch's flagship development stage product candidates, known as the AC5 Surgical Hemostatic Device™ and AC5 Topical Hemostatic Device™, are being designed to achieve hemostasis during surgical, wound and interventional care.

Notice Regarding Forward-Looking Statements

This news release contains "forward-looking statements" as that term is defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release that are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, references to novel technologies and methods, our business and product development plans and projections, or market information. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with developing new products or technologies and operating as a development stage company, our ability to retain important members of our management team and attract other qualified personnel, our ability to raise the additional funding we will need to continue to pursue our business and product development plans, our ability to obtain required regulatory approvals, our ability to develop and commercialize products based on our technology platform, and market conditions. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in the reports and other documents we file with the SEC, available at www.sec.gov.

Terrence W. Norchi, MD
Arch Therapeutics, Inc.